Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

EML4 (EMAP Like 4)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

AmoyDx® EML4-ALK Fusion Gene Detection Kit

Lung Cancer Mutation Panel

QFusion™ EML4-ALK and KIF5B-ALK Fusion Gene Detection Test

AmoyDx® EML4-ALK Fusion Gene Detection Kit

Lung Cancer Mutation Panel

QFusion™ EML4-ALK and KIF5B-ALK Fusion Gene Detection Test

›

EML4-ALK variant 1	Non Small Cell Lung Cancer	EML4-ALK variant 1	Non Small Cell Lung Cancer	lorlatinib Sensitive: B - Late Trials lorlatinib Sensitive : B	lorlatinib Sensitive: B - Late Trials lorlatinib Sensitive : B
EML4-ALK variant 3	Non Small Cell Lung Cancer	EML4-ALK variant 3	Non Small Cell Lung Cancer	lorlatinib Sensitive: B - Late Trials lorlatinib Sensitive : B	lorlatinib Sensitive: B - Late Trials lorlatinib Sensitive : B
EML4-ALK fusion + ALK rearrangement	Non Small Cell Lung Cancer	EML4-ALK fusion + ALK rearrangement	Non Small Cell Lung Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
EML4-ALK variant 3a	Non Small Cell Lung Cancer	EML4-ALK variant 3a	Non Small Cell Lung Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
EML4-ALK fusion + ALK positive	Non Small Cell Lung Cancer	EML4-ALK fusion + ALK positive	Non Small Cell Lung Cancer	crizotinib Resistant: C3 – Early Trials crizotinib Resistant : C3	crizotinib Resistant: C3 – Early Trials crizotinib Resistant : C3
EML4-ALK variant 3b	Non Small Cell Lung Cancer	EML4-ALK variant 3b	Non Small Cell Lung Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
EML4-ALK variant 1	Non Small Cell Lung Cancer	EML4-ALK variant 1	Non Small Cell Lung Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
EML4-ALK rearrangement	Non Small Cell Lung Cancer	EML4-ALK rearrangement	Non Small Cell Lung Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EML4_E6-ALK_E18(V3)	Non Small Cell Lung Cancer	EML4_E6-ALK_E18(V3)	Non Small Cell Lung Cancer	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3	ensartinib Resistant: C3 – Early Trials ensartinib Resistant : C3
EML4-NTRK3 fusion	Solid Tumor	EML4-NTRK3 fusion	Solid Tumor	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3
ALK-EML4_V3	Non Small Cell Lung Cancer	ALK-EML4_V3	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3